Advertisements

Asthmanefrin (Adrenaline)

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Asthmanefrin (Adrenaline)

What is Asthmanefrin (Adrenaline)?

Asthmanefrin is an over-the-counter medication containing racepinephrine, a bronchodilator. It is a synthetic form of adrenaline, also known as epinephrine, which is a hormone and neurotransmitter naturally produced by the body.

Mechanism of Action

As a sympathomimetic agent, racepinephrine works by stimulating specific receptors in the airway known as adrenergic receptors. When these receptors are activated, the smooth muscles surrounding the bronchial tubes relax. This physiological response, known as bronchodilation, results in the widening of the airways.

Purpose and Use

The primary function of this medication is to provide temporary relief from the symptoms associated with bronchial asthma. By dilating the airways, it helps to alleviate:

  • Shortness of breath
  • Wheezing
  • Tightness in the chest

Unlike long-term maintenance therapies, this type of medication is intended for the intermittent relief of mild symptoms. It is typically delivered in a localized manner to the lungs via inhalation, often using a specialized nebulizer system that converts the liquid medication into a fine mist.

Regulatory References

  1. MedlinePlus Drugs
  2. DailyMed NDC 0487-2784
Advertisements

What side effects are possible with Asthmanefrin (Adrenaline)?

Possible side effects and safety information

The safety profile of Racepinephrine, a sympathomimetic agent, is characterized by documented systemic effects arising from the stimulation of the sympathetic nervous system. The official regulatory labeling for this inhalation solution does not provide formal frequency classifications (e.g., common, rare).


Adverse Reactions by System-Organ Class

The most characteristic adverse reactions documented in regulatory sources fall into specific system categories:

  • Cardiac Disorders: Increased heart rate (tachycardia) and rapid or irregular heartbeat (palpitations) are typical systemic effects.
  • Nervous System and Psychiatric Disorders: Stimulation can lead to tremor, headache, dizziness, nervousness, apprehension, and insomnia.
  • Gastrointestinal Disorders: Nausea is a documented adverse reaction.

Serious Safety Constraints

Although rare, the official safety documentation highlights the potential for serious adverse reactions. These include the risk of seizure and paradoxical bronchospasm, a sudden, severe worsening of breathing difficulties immediately following use. Furthermore, there is a documented risk of heart attack or stroke resulting from the rise in heart rate and blood pressure, particularly in individuals with pre-existing conditions or when the product is used in excess.


Population-Specific Safety Considerations

The systemic stimulant effects require caution in individuals with specific pre-existing health conditions, as stated in the regulatory label. These conditions include heart disease, high blood pressure, thyroid disease, diabetes, glaucoma, and prostate problems that cause difficulty urinating. The label also contains a Sulfite Allergy Alert, noting that the solution contains sulfites which may trigger allergic or asthmatic episodes in susceptible persons.

Simultaneous use is constrained by specific drug interactions, notably a prohibition against use with Monoamine Oxidase Inhibitors (MAOIs), or within two weeks of stopping them, and a warning against co-administration with other stimulants.

Advertisements

Overdose and Emergency Response

Official Overdose Profile and Emergency Action

Overdose Component Regulatory Findings
Documented Manifestations Overdose may present with signs of excessive stimulation, including extremely elevated arterial pressure (hypertension), tachycardia, tremors, nervousness, seizure, pallor, headache, and vomiting.
Life-Threatening Outcomes Regulatory documents list potentially fatal cardiac arrhythmias, including ventricular fibrillation, stroke, heart attack, and pulmonary oedema. Metabolic acidosis and kidney failure are also documented risks.
Emergency Action Required Immediate medical help or contacting a Poison Control Center is mandated right away in case of overdose. Help must be sought if use exceeds 12 inhalations in 24 hours, or if symptoms worsen or are not better in 20 minutes.
Treatment Approach No specific antidote is known. Treatment is symptomatic and supportive. It may include the use of rapidly acting vasodilators or alpha-adrenergic blocking drugs for severe hypertension, and beta-adrenergic blocking drugs for cardiac arrhythmias.
Population Consideration The official label notes an increased risk of cerebrovascular hemorrhage in elderly patients following overdose.

Connection to the Overall Overdose Profile

The regulatory profile defines overdose by listing severe cardiovascular and neurological complications resulting from excessive stimulation. This high-risk physiological structure necessitates the explicit instruction to seek emergency attention immediately upon signs of overdose or use exceeding the maximum daily inhalation threshold. The documented management approach is primarily supportive, targeting the reversal of critical symptoms using specific pharmacological agents.

Advertisements

Therapeutic Uses of Asthmanefrin (Adrenaline)

What Asthmanefrin (Adrenaline) Treats: Main Uses and Benefits

Asthmanefrin is commonly used for temporary, short-term relief of mild, intermittent asthma symptoms. It is applied across domains where additional symptomatic support is needed, primarily in situations involving symptoms related to systemic imbalance and heightened physiological activity.

This medication is relevant for use in conditions where symptoms may intensify temporarily, such as during mild intermittent asthma episodes. It is commonly used when symptoms cluster into patterns requiring supportive management, providing a therapeutic benefit that helps ease the overall symptom burden.

The medication is commonly used across conditions characterized by periods of heightened symptoms, particularly those involving acute or disruptive episodes that create noticeable physiological strain. It offers symptomatic relief when groups of symptoms appear suddenly or fluctuate, contributing to improved comfort during these periods. This treatment is applied in scenarios where additional management of discomfort is required.


Quick Fact: Relief for Respiratory Symptoms

Asthmanefrin helps support the patient during difficult episodes by easing distress. It is commonly used for short-term symptomatic assistance during acute changes related to physical discomfort.

Regulatory References

  1. NIH DailyMed Label
Advertisements

Eligibility and Restrictions for Use

The official regulatory profile for Asthmanefrin (Racepinephrine) Inhalation Solution strictly defines who is eligible for self-treatment. Use is approved for adults and children 4 years of age and over who have received a doctor-confirmed diagnosis of asthma.


Contraindicated Use

Regulatory documents state the medicine must not be used by individuals currently taking a prescription Monoamine Oxidase Inhibitor (MAOI), or within two weeks of discontinuing one. Furthermore, use is strictly contraindicated for individuals who have not been told by a doctor that they have asthma.


Conditional Eligibility

Eligibility is restricted for several populations, requiring users to ask a health professional before use. This conditional status applies to individuals with pre-existing medical conditions, including heart disease, high blood pressure, diabetes, thyroid disease, seizures, or narrow angle glaucoma. Additionally, children under 4 years of age are not an established population for this product, and its use during pregnancy or breastfeeding requires prior professional consultation.

Advertisements

What should I know about interactions with other medicines?

The active ingredient in Asthmanefrin, Racepinephrine, engages in officially documented interaction patterns primarily through metabolic interference and pharmacodynamic effects, as classified by regulatory agencies.

Interaction Severity Interacting Agent Class Required Action / Outcome
Contraindicated Monoamine Oxidase Inhibitors (MAOIs) Use is prohibited; must observe a two-week separation period.
Potentiation Tricyclic Antidepressants, COMT Inhibitors, Sympathomimetic Agents Risk of severe, prolonged hypertension or additive effects.
Antagonism Beta-Adrenergic Blocking Drugs, Alpha-Adrenergic Blocking Drugs Officially documented to counteract the bronchodilating and pressor effects.

Co-administration with MAOIs is formally classified as a contraindicated combination due to severely impaired metabolism, leading to significant potentiation of the pressor effect. This metabolic interference requires a strict two-week separation period after the MAOI drug is discontinued.

The pharmacodynamic profile includes potentiation with agents such as Thyroid Hormones, documented to increase the risk of severe blood pressure elevation. Other agents, including Cardiac Glycosides and Halogenated Hydrocarbon Anesthetics, are officially associated with an increased arrhythmogenic potential. Use must also be avoided with stimulant dietary supplements as stated in official labeling.

Advertisements

Mechanism of Action

Reversal of Airway Constriction via beta2 Receptor Agonism

Racepinephrine primarily functions as a direct agonist at the beta2-adrenergic receptors (beta2 AR) on bronchial smooth muscle. This interaction rapidly stimulates the cAMP signaling cascade, leading to the relaxation of the muscle fibers. This mechanism produces bronchodilation, which is the physiological widening of the constricted airways, increasing the internal diameter of the airway lumen.

Airway Decongestion via alpha1 Receptor Activation

The drug also engages the alpha1-adrenergic receptors (alpha1 AR) found in the blood vessels of the bronchial lining. Activation of these receptors induces immediate vasoconstriction, which is the physiological narrowing of the local blood vessels. This action reduces fluid leakage into the tissues, resulting in the reduction of mucosal fluid that acts to reduce the tissue volume lining the airways.

Mechanistic Limitation: Receptor Desensitization

The non-selective nature of the molecule and the high-affinity engagement of the beta2 receptor pathway is subject to receptor desensitization (tachyphylaxis). This is a biological constraint where frequent exposure can lead to the phosphorylation and uncoupling of the beta2 receptors, causing the bronchodilatory mechanism to become progressively less responsive over time.

Advertisements

Dosage and Administration Information

How to Use Asthmanefrin (Adrenaline)

Asthmanefrin is a racemic epinephrine solution formulated exclusively for inhalation via a nebulizer system, serving as a non-prescription medication for temporary symptom relief. This administration route ensures targeted delivery of the 2.25% racepinephrine solution directly to the respiratory tract, where it is intended to act.


Official Dosing and Frequency

The usage of the medication is governed by specific maximum dose and time-frequency constraints outlined in official labeling. The standard application involves administering 1 to 3 inhalations per dose. Each treatment requires preparing the nebulizer with the full contents of one 0.5 mL vial of the solution. These usage parameters define the boundaries for appropriate self-management.

Usage Constraint Official Limit (Adults and Children 4 years and over)
Minimum Dosing Interval Not more often than every 3 hours
Maximum Daily Limit Not more than 12 inhalations in 24 hours

Administration and Age Constraints

The product's administration is tied to specific procedural requirements. The 0.5 mL solution must be added to an appropriate nebulizer device, such as a hand-held rubber bulb nebulizer, for delivery. The medication is officially approved for use in adults and children 4 years of age and over.

For pediatric patients under the age of four, instructions state that use should only occur following medical consultation. Furthermore, the administration of the solution to children in the approved age group must be conducted under adult supervision.

Official instructions also set a necessary condition for professional review: if symptoms are not better within 20 minutes after use, or if the 12-inhalation daily maximum is consistently required, medical attention must be sought. This acts as a procedural safeguard tied to the medication's intended role for temporary use.

Advertisements

Recent Clinical Evidence

Evidence for Temporary Relief of Mild Intermittent Asthma Symptoms (OTC Use)

The regulatory status for Racepinephrine, the active ingredient, is based on a regulatory monograph supported by a collection of scientific data, including historical use and controlled trials. Research was studied for its use in individuals experiencing temporary, mild symptoms associated with conditions characterized by fluctuating or episodic manifestations. The available studies include controlled clinical trials that examined outcomes when the drug was compared against a placebo or other active agents.

In these investigations, researchers monitored objective changes in pulmonary function measures, such as the forced expiratory volume in one second (FEV1), which is a measurement of lung function. Findings describe patterns observed in the studies related to measurements taken shortly after inhalation, which contributes to understanding the temporary physiological changes observed in some studies.

Supporting Research Context and Limitations

Beyond the Over-the-Counter indication, the active ingredient was studied in acute care settings, such as in pediatrics for conditions associated with acute airway obstruction (croup). This supporting research context is used to describe the broader scientific characteristics of the active ingredient, but these findings do not inform self-management for the OTC indication.

Long-term effects are not well established for continuous, as-needed use, as most trials observe responses over a limited time interval. Data are limited regarding long-term outcomes and the potential for a diminished response over time. Evidence quality varies across studies, and comparative evidence against modern prescription treatments is lacking in large-scale modern trials, making it difficult to fully contextualize the drug in the current range of available treatments. Data for certain groups, such as the elderly or those with co-occurring medical conditions, also remain limited.

Key Studies & References

  1. ASTHMANEFRIN - racepinephrine hydrochloride solution (Product Labeling, DailyMed)
  2. Prospective randomized double-blind study comparing L-epinephrine and racemic epinephrine aerosols in the treatment of laryngotracheitis (croup)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Asthmanefrin (Adrenaline) (FAQ)


Q: Is Asthmanefrin the same thing as an EpiPen?

Asthmanefrin is not the same as an EpiPen. The active ingredient in both products is based on epinephrine, but Asthmanefrin contains racepinephrine and is an inhalation solution for temporary relief of mild asthma symptoms. The EpiPen injector uses a different, single-enantiomer form of epinephrine and is designed for the acute, emergency treatment of severe allergic reactions.


Q: Why did the old Primatene Mist get replaced by drugs like Asthmanefrin?

Official information states that older epinephrine inhalers, such as Primatene Mist, were phased out due to environmental regulations. The removal was mandated by the Montreal Protocol, which required the international phase-out of the chlorofluorocarbon (CFC) propellants used in those original products.


Q: Does Asthmanefrin contain steroids?

No, Asthmanefrin does not contain steroids. According to regulatory labeling, its sole active ingredient is Racepinephrine. This compound is pharmacologically classified as a sympathomimetic agent, which is a type of adrenergic bronchodilator.


Q: Can Asthmanefrin be used for exercise-induced breathing issues?

Official product information indicates the drug is for the temporary relief of mild symptoms of intermittent asthma. The regulatory label does not specifically address 'exercise-induced' breathing issues. Use of the medication is limited to individuals who have received a doctor's confirmed diagnosis of asthma.


Q: What is the main difference between Asthmanefrin and prescription asthma medicines?

A primary difference is that Asthmanefrin is available as an Over-the-Counter (OTC) medicine intended only for the temporary relief of mild, intermittent asthma symptoms. Prescription asthma medications are typically formulated and authorized for ongoing maintenance or for managing more severe or chronic respiratory conditions.


Q: How long do the effects of Asthmanefrin usually last?

Regulatory documents limit how often the dose may be repeated, stating it should be no more often than every three hours, which reflects its classification for temporary relief.


Q: Does Asthmanefrin interact with common cold or flu medications?

Regulatory labeling advises consulting a health professional if you are taking drugs that contain certain ingredients found in cold, flu, or allergy medicines. This caution applies to ingredients like pseudoephedrine, phenylephrine, or ephedrine because they are known to potentially lead to additive cardiovascular effects.


Q: Does Asthmanefrin expire quickly?

Official storage guidelines indicate that any solution remaining in an opened vial should be used immediately and then discarded. To maintain stability, the individual vials are designed to be kept sealed in their foil pouch until immediately before use.


Q: Does Asthmanefrin cause weight gain?

Weight gain is not listed as a documented adverse reaction in the regulatory labeling for this product. The commonly reported side effects are generally stimulant-related, such as nervousness, tremor, and increased heart rate.


Q: Are there any food restrictions when using Asthmanefrin?

Official product labeling contains warnings about foods and beverages that contain caffeine and advises against their use while taking this medication. Additionally, it is advised against using dietary supplements that are reported to have a stimulant effect, as these can increase certain side effects.


Q: What kind of side effects affect the mouth or throat when using Asthmanefrin?

The documented adverse reactions listed in official documents are categorized as affecting the cardiac, nervous system, psychiatric, and gastrointestinal systems. Local effects specifically on the mouth or throat are not listed in the official adverse reactions profile.


Q: Is there a risk of becoming dependent on Asthmanefrin?

The official label does not use the term dependency. However, official warnings caution that needing the medication frequently or exceeding the maximum recommended use may be a sign that asthma symptoms are worsening. This pattern is noted as requiring immediate consultation with a health professional.


Q: Does Asthmanefrin have a strong taste or smell?

Specific taste or smell characteristics are not detailed in the official product information. The solution is formulated as a sterile, preservative-free aqueous solution designed for inhalation, which is the primary route of administration.


Q: What does 'bronchial asthma' mean in relation to Asthmanefrin?

The term 'bronchial asthma' is used in the product's indication to describe the symptoms that occur when the airways (bronchi) become constricted or narrowed. The medication is intended to temporarily relieve the resulting symptoms like wheezing and shortness of breath.


Q: Does taking certain vitamins affect how Asthmanefrin works?

While the official labeling does not specifically mention vitamins, official product information suggests consulting a healthcare professional before using any herbal or vitamin supplements. This is to rule out any potential for unknown or stimulant-related interactions with the active ingredient.


Q: What is the difference between epinephrine and adrenaline in Asthmanefrin?

In this context, there is no chemical difference, as epinephrine is also known as adrenaline. The product specifically contains Racepinephrine, which is the synthetic, racemic mixture of both the L- and D-forms of Epinephrine/Adrenaline.


Q: Is Asthmanefrin ever used in emergency situations?

Asthmanefrin is classified as an Over-the-Counter rescue medication intended for mild symptoms. The regulatory label instructs users to seek immediate medical attention for any serious or sudden worsening of breathing, or in the case of overdose, to contact a Poison Control Center immediately.


Q: What are the main components of the Asthmanefrin device kit?

The product consists of the Racepinephrine Inhalation Solution supplied in individual single-use vials. Official instructions require that this solution must be administered using an appropriate nebulizer device, such as a hand-held rubber bulb nebulizer, which is typically purchased separately or as part of a kit.


Q: Is Asthmanefrin used to treat chronic obstructive pulmonary disease (COPD)?

No, Asthmanefrin is not authorized to treat Chronic Obstructive Pulmonary Disease (COPD). The official indication is strictly limited to the temporary relief of mild symptoms of intermittent asthma, and the label warns against use without a doctor-confirmed asthma diagnosis.


Q: Does Asthmanefrin interact with pain relievers like ibuprofen?

Regulatory labeling advises caution if taking drugs for pain that also contain stimulants or caffeine. If a pain reliever, regardless of the active ingredient, contains caffeine or a stimulant component, official information suggests consulting a health professional before use.

Advertisements

How should Asthmanefrin (Adrenaline) be stored and disposed of?

Storage and Disposal Requirements

Asthmanefrin (Racepinephrine) Inhalation Solution must be stored according to regulatory requirements to preserve its stability.


Storage Conditions

Condition Requirement
Temperature Store between 2 C and 25 C (36 F and 77 F).
Protection Protect from light, freezing, and excessive heat.
Vial Integrity Do not use the solution if it appears brown in color or cloudy.
Child Safety Keep the product out of reach of children.

Disposal Instructions

Disposal should follow official guidelines. The preferred method for discarding unused or expired product is a drug take-back program. If a program is unavailable, the solution should be mixed with an undesirable substance (e.g., dirt, coffee grounds) in a sealed container and then discarded in the household trash. Racepinephrine is not on the FDA's list of medicines recommended for flushing.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Asthmanefrin (Adrenaline) found in:

A-Z Index: